Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma

Autores
Marquez Conde, Carlos Alexei; Miceli, Diego Daniel
Año de publicación
2026
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
A 12-year-old male neutered domestic shorthair cat was referred with severe polyphagia, polydipsia, polyuria, weight gain, and signs of neurological disease, including blindness, head tilt, and ataxia. Magnetic resonance imaging (MRI) identified a suprasellar mass consistent with a pituitary macroadenoma. Hypersomatotropism (HST) was diagnosed based on phenotypic changes compatible with acromegaly and an abnormally high serum insulin-like growth factor 1 (IGF-1) concentration (1253 ng/ml). Medical treatment with cabergoline monotherapy (10 µg/kg PO q24h) was prescribed. Progressive improvement of clinical signs was observed, accompanied by a gradual decrease in serum IGF-1 concentrations. Based on clinical and hormonal response, the dosing interval was sequentially extended to q48h and subsequently to q72h. By week 16 oftreatment, signs of neurological disease had resolved and serum IGF-1 concentration had normalized (749 ng/ml), while visual deficits persisted. By week 30, signs of neurological disease remained absent, serum IGF-1 concentration was maintained within the reference interval,and diabetes mellitus did not develop. Cabergoline was well tolerated, with mild gastrointestinal signs reported early in the course of treatment. Relevance and novel information: this report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustainedclinical and biochemical control with cabergoline monotherapy. This case demonstrates that dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurological disease.
Fil: Marquez Conde, Carlos Alexei. No especifíca;
Fil: Miceli, Diego Daniel. Universidad Maimónides; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
GH EXCESS
DOPAMINE AGONIST
PITUITARY TUMOR
ACROMEGALY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/289905
Acceder
id CONICETDig_e8708967c883c619b53f076dcfbda2f3
oai_identifier_str oai:ri.conicet.gov.ar:11336/289905
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenomaMarquez Conde, Carlos AlexeiMiceli, Diego DanielGH EXCESSDOPAMINE AGONISTPITUITARY TUMORACROMEGALYhttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4A 12-year-old male neutered domestic shorthair cat was referred with severe polyphagia, polydipsia, polyuria, weight gain, and signs of neurological disease, including blindness, head tilt, and ataxia. Magnetic resonance imaging (MRI) identified a suprasellar mass consistent with a pituitary macroadenoma. Hypersomatotropism (HST) was diagnosed based on phenotypic changes compatible with acromegaly and an abnormally high serum insulin-like growth factor 1 (IGF-1) concentration (1253 ng/ml). Medical treatment with cabergoline monotherapy (10 µg/kg PO q24h) was prescribed. Progressive improvement of clinical signs was observed, accompanied by a gradual decrease in serum IGF-1 concentrations. Based on clinical and hormonal response, the dosing interval was sequentially extended to q48h and subsequently to q72h. By week 16 oftreatment, signs of neurological disease had resolved and serum IGF-1 concentration had normalized (749 ng/ml), while visual deficits persisted. By week 30, signs of neurological disease remained absent, serum IGF-1 concentration was maintained within the reference interval,and diabetes mellitus did not develop. Cabergoline was well tolerated, with mild gastrointestinal signs reported early in the course of treatment. Relevance and novel information: this report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustainedclinical and biochemical control with cabergoline monotherapy. This case demonstrates that dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurological disease.Fil: Marquez Conde, Carlos Alexei. No especifíca;Fil: Miceli, Diego Daniel. Universidad Maimónides; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaSAGE Publications2026-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/289905Marquez Conde, Carlos Alexei; Miceli, Diego Daniel; Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma; SAGE Publications; Journal of Feline Medicine and Surgery Open Reports; 12; 1; 4-2026; 1-52055-1169CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/20551169261448336info:eu-repo/semantics/altIdentifier/doi/10.1177/20551169261448336info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:53:22Zoai:ri.conicet.gov.ar:11336/289905instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:53:23.065CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
title Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
spellingShingle Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
Marquez Conde, Carlos Alexei
GH EXCESS
DOPAMINE AGONIST
PITUITARY TUMOR
ACROMEGALY
title_short Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
title_full Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
title_fullStr Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
title_full_unstemmed Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
title_sort Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma
dc.creator.none.fl_str_mv Marquez Conde, Carlos Alexei
Miceli, Diego Daniel
author Marquez Conde, Carlos Alexei
author_facet Marquez Conde, Carlos Alexei
Miceli, Diego Daniel
author_role author
author2 Miceli, Diego Daniel
author2_role author
dc.subject.none.fl_str_mv GH EXCESS
DOPAMINE AGONIST
PITUITARY TUMOR
ACROMEGALY
topic GH EXCESS
DOPAMINE AGONIST
PITUITARY TUMOR
ACROMEGALY
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv A 12-year-old male neutered domestic shorthair cat was referred with severe polyphagia, polydipsia, polyuria, weight gain, and signs of neurological disease, including blindness, head tilt, and ataxia. Magnetic resonance imaging (MRI) identified a suprasellar mass consistent with a pituitary macroadenoma. Hypersomatotropism (HST) was diagnosed based on phenotypic changes compatible with acromegaly and an abnormally high serum insulin-like growth factor 1 (IGF-1) concentration (1253 ng/ml). Medical treatment with cabergoline monotherapy (10 µg/kg PO q24h) was prescribed. Progressive improvement of clinical signs was observed, accompanied by a gradual decrease in serum IGF-1 concentrations. Based on clinical and hormonal response, the dosing interval was sequentially extended to q48h and subsequently to q72h. By week 16 oftreatment, signs of neurological disease had resolved and serum IGF-1 concentration had normalized (749 ng/ml), while visual deficits persisted. By week 30, signs of neurological disease remained absent, serum IGF-1 concentration was maintained within the reference interval,and diabetes mellitus did not develop. Cabergoline was well tolerated, with mild gastrointestinal signs reported early in the course of treatment. Relevance and novel information: this report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustainedclinical and biochemical control with cabergoline monotherapy. This case demonstrates that dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurological disease.
Fil: Marquez Conde, Carlos Alexei. No especifíca;
Fil: Miceli, Diego Daniel. Universidad Maimónides; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description A 12-year-old male neutered domestic shorthair cat was referred with severe polyphagia, polydipsia, polyuria, weight gain, and signs of neurological disease, including blindness, head tilt, and ataxia. Magnetic resonance imaging (MRI) identified a suprasellar mass consistent with a pituitary macroadenoma. Hypersomatotropism (HST) was diagnosed based on phenotypic changes compatible with acromegaly and an abnormally high serum insulin-like growth factor 1 (IGF-1) concentration (1253 ng/ml). Medical treatment with cabergoline monotherapy (10 µg/kg PO q24h) was prescribed. Progressive improvement of clinical signs was observed, accompanied by a gradual decrease in serum IGF-1 concentrations. Based on clinical and hormonal response, the dosing interval was sequentially extended to q48h and subsequently to q72h. By week 16 oftreatment, signs of neurological disease had resolved and serum IGF-1 concentration had normalized (749 ng/ml), while visual deficits persisted. By week 30, signs of neurological disease remained absent, serum IGF-1 concentration was maintained within the reference interval,and diabetes mellitus did not develop. Cabergoline was well tolerated, with mild gastrointestinal signs reported early in the course of treatment. Relevance and novel information: this report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustainedclinical and biochemical control with cabergoline monotherapy. This case demonstrates that dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurological disease.
publishDate 2026
dc.date.none.fl_str_mv 2026-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/289905
Marquez Conde, Carlos Alexei; Miceli, Diego Daniel; Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma; SAGE Publications; Journal of Feline Medicine and Surgery Open Reports; 12; 1; 4-2026; 1-5
2055-1169
CONICET Digital
CONICET
url http://hdl.handle.net/11336/289905
identifier_str_mv Marquez Conde, Carlos Alexei; Miceli, Diego Daniel; Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma; SAGE Publications; Journal of Feline Medicine and Surgery Open Reports; 12; 1; 4-2026; 1-5
2055-1169
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/20551169261448336
info:eu-repo/semantics/altIdentifier/doi/10.1177/20551169261448336
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874774835724288000
score 13.24418

Publicaciones similares